SUNITINIB STADA 12,5MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sunitinib stada 12,5mg tvrdá tobolka

stada arzneimittel ag, bad vilbel array - 17420 sunitinib - tvrdá tobolka - 12,5mg - sunitinib

SUNITINIB STADA 25MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sunitinib stada 25mg tvrdá tobolka

stada arzneimittel ag, bad vilbel array - 17420 sunitinib - tvrdá tobolka - 25mg - sunitinib

SUNITINIB STADA 50MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sunitinib stada 50mg tvrdá tobolka

stada arzneimittel ag, bad vilbel array - 17420 sunitinib - tvrdá tobolka - 50mg - sunitinib

Sutent Evropská unie - čeština - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastická činidla - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Sunitinib Accord Evropská unie - čeština - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastická činidla - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

KLERTIS 12,5MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

klertis 12,5mg tvrdá tobolka

egis pharmaceuticals plc, budapešť array - 37 sunitinib cyklamÁt - tvrdá tobolka - 12,5mg - sunitinib

KLERTIS 25MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

klertis 25mg tvrdá tobolka

egis pharmaceuticals plc, budapešť array - 37 sunitinib cyklamÁt - tvrdá tobolka - 25mg - sunitinib

KLERTIS 50MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

klertis 50mg tvrdá tobolka

egis pharmaceuticals plc, budapešť array - 37 sunitinib cyklamÁt - tvrdá tobolka - 50mg - sunitinib

SUNITINIB GLENMARK 12,5MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sunitinib glenmark 12,5mg tvrdá tobolka

glenmark pharmaceuticals s.r.o., praha array - 17420 sunitinib - tvrdá tobolka - 12,5mg - sunitinib

SUNITINIB GLENMARK 25MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sunitinib glenmark 25mg tvrdá tobolka

glenmark pharmaceuticals s.r.o., praha array - 17420 sunitinib - tvrdá tobolka - 25mg - sunitinib